arrow
D

Darren R. Feldman

Memorial Sloan Kettering Cancer Center
H指数:54
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

24 一项关于阿贝西利联合卡博替尼在免疫检查点阻断预处理后的转移性透明细胞肾细胞癌和转位相关肾细胞癌中的1b/2期研究(NCT06835972)

2026-09-020
OAAI
78 Dietary Fructose Intake and Tumoral Fructose-Metabolism Gene Expression in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

78 饮食果糖摄入与接受免疫检查点阻断治疗转移性肾细胞癌的肿瘤果糖代谢基因表达

2026-09-020
OAAI
Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study

顺铂剂量、肾功能及其他因素对来自《白金研究》的1400多名成年期癌症幸存者听力学评估性耳毒性的影响:一项多中心队列研究

2026-03-310
OAAI
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma

一项关于talazoparib和axitinib治疗晚期透明细胞肾细胞癌的1b/2期研究

2025-03-290
PRE
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial (vol 86, pg 90, 2024)

卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌:一项II期试验的更新结果(卷86,页90,2024)

2025-01-010
PRE
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

畸胎瘤对转移性非精原细胞性生殖细胞癌患者生存概率的影响: IGCCCG更新联盟的结果

2024-05-010
PRE